ProBioGen AG has appointed Simon Johannes Bulling as chief operating officer to lead operational business and oversee the manufacture of innovative biologics across the German company’s growing portfolio. An experienced executive from biopharma and the contract development and manufacturing organisation (CDMO) sector, Dr Bulling has a track record in scaling operations, building performance and translating strategy into measurable results.
Before joining ProBioGen, Dr Bulling was site head at Celonic and a member of the executive committee. He previously held senior roles at Recipharm, Rentschler Biopharma, Vetter Pharma and Sandoz. Dr Bulling holds a PhD in molecular signal transduction from the Medical University of Vienna, Austria. ProBioGen specialises in developing and manufacturing biopharmaceutical active ingredients, viral vectors, and vaccines. The company is planning to establish a GMP manufacturing facility for cell therapies in Berlin.
ProBioGen announced the appointment on 21 April 2026.
Copyright 2026 Evernow Publishing Ltd.